扶正祛邪養(yǎng)陰方聯(lián)合NP方案、信迪利單抗治療氣陰兩虛型晚期非小細(xì)胞肺癌患者的效果

打開(kāi)文本圖片集

[Abstract]Objective： To analyze the effcts of the Fuzheng Quxie Yangyin Formula combined of Navelbine + Cisplatin （NP）regimen and Sintilimab on patients with advanced non-smallcellung cancer（NSCLC）of Qi and Yin deficiencytype.Method：A total of 12O patients with advanced NSCLCof Qi and Yindeficiency type were treatedat Fujian Tingzhou Hospitalfrom January 2O2O to December 2023.They were divided into two groups using a random number table method， with 6O cases in each group.The control group was treated with NP regimencombined with Sintilimab，while the observation group was treated with Fuzheng Quxie Yangyin Formulaonthe basis of the control group.The therapeutic efects，occurrence of adverse reactions，traditional Chinese medicine syndrome scores，tumor markersand immune function levels of the two groups were compared.Result：The total effective rate of recent treatment in theobservation group was higherthanthatinthe controlgroup，and the incidenceof adversereactions waslower than that in the control group，the differences were statistically significant （ P <0.05）.After treatment， the traditional Chinese medicine syndrome score， tumor marker levels and CD8 ?+ in the observation group were lower than those in the control group，while CD 3+ and CD 4+ were higher than those in the control group，the differences were statistically significant （P<0.05 ）.Conclusion： Fuzheng Quxie Yangyin Formula combined with NP regimen and Sintilimabcan reduce thelevels of tumor markers and improve immune function in patients with advanced NSCLC of Qiand Yindeficiency type，with fewer adverse reactions.

[Keywords]Advanced non-smallcell lung cancerQi and Yin deficiency typeFuzheng Quxie Yangyin Formula Immune function Adverse reactions

First-author's address： Department 3 of Internal Medicine，F(xiàn)ujian Tingzhou Hospital， Changting 366300， China

非小細(xì)胞肺癌（NSCLC）是肺癌的常見(jiàn)類(lèi)型，占所有肺癌的 80% 左右[-2]。（剩余5855字）